The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
What exciting updates on maintenance therapy in AML were presented at ASH 2023?
Featured:
Gail J. RobozAt the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Gail Roboz, Weill Cornell Medicine, New York, US, shared her insights with the AML Hub. We asked “What exciting updates on maintenance therapy in acute myeloid leukemia were presented at ASH 2023?”
What exciting updates on maintenance therapy in acute myeloid leukemia were presented at ASH 2023?
Roboz discusses the use of oral azacitidine as a maintenance therapy for patients with acute myeloid leukemia, highlighting results from the QUAZAR AML-001 trial, before exploring the impact of maintenance therapy on measurable residual disease status and postremission outcomes. She reviews the optimal selection of maintenance therapies, and how measurable residual disease status can influence treatment decisions in subgroups such as NPM1-mutated and FLT3-mutated AML. Roboz concludes by emphasizing the need for more randomized clinical trials evaluating maintenance therapies and considers future directions, including menin inhibitors and high-sensitivity measurable residual disease testing.
